SITE UNDER CONSTRUCTION: Currently we are in the process of upgrading this WEBSITE.
Encouraging studies against pulmonary fibrosis and metastatic breast and ovarian cancer from ozes biopharma
OZES BIOPHARMA was established at “Technocity of ANTALYA/TURKEY” located at the campus of Akdeniz University in December 2014 by Prof.Dr.Osman Nidai OZES. Dr.OZES is an expert scientist in molecular oncology, molecular immunology, type 2 diabetes and fibrosis.
Dr.OZES recieved his Ph.D from Indiana University, Bloomington/IN/USA in 1993, did his postdoctoral work at Walter Oncology Center at IUPUI for 4 years, then joined to InterMune Inc. in 2002 and worked there for five years to elucidate molecular mechanism of action of anti-fibrotic drug candidate, pirfenidone. FDA recently approved clinical use of Pirfenidone (Esbriest) against idiopathic pulmonary fibrosis, IPF.
Although there are 2 drugs approved by FDA against IPF we believe there is stil need for development of new drugs against lung, kidney, liver fibrosis and NASH. Taking all these in account OZES BIOPHARMA is searching for more potent drug candidates against above indications. In past four years, we isolated biologicaly active compounds capable of inhibiting TGF-induced fibrotic proteins such as collagen, fibronectin and elastin, and applied to Turkish Patent Office. Our application passed initial screning and recieved protection for 15 months in 165 countries. , and we are now in the process.
Aside from its anti-fibrotic activities the compounds, which are under patent protection, are also very effective against growth and metastasis of breast and cisplatin resistant ovarian carcinoma cells. Currently, we are in the process of filing EPC and PCT for above compounds.